AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Aditxt, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00RDV1WT4
0.00▼ 0.00 (-33.33%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
0.00
Day's Range
0.00 – 0.00
52-Week Range
0.00 – 7.13
Volume
868.7K
Avg Volume
12.0M
Share Statistics
Shares Outstanding
Employees
26
Exchange
XNAS
Listed
2020-06-30
Share count as of May 20, 2026

Aditxt, Inc. Common Stock (ADTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Aditxt, Inc. Common Stock (ADTX)
What is Aditxt, Inc. Common Stock's Market Cap?
Aditxt, Inc. Common Stock's Market Cap is $326.37, based on as-reported figures from SEC (XBRL) filings.
What is Aditxt, Inc. Common Stock's Price / Sales?
Aditxt, Inc. Common Stock's Price / Sales is 0.0×, based on as-reported figures from SEC (XBRL) filings.
What is Aditxt, Inc. Common Stock's Revenue (TTM)?
Aditxt, Inc. Common Stock's Revenue (TTM) is $14.3K, based on as-reported figures from SEC (XBRL) filings.
What is Aditxt, Inc. Common Stock's Net Income (TTM)?
Aditxt, Inc. Common Stock's Net Income (TTM) is -$53.3M, based on as-reported figures from SEC (XBRL) filings.
What is Aditxt, Inc. Common Stock's EBITDA?
Aditxt, Inc. Common Stock's EBITDA is -$18.1M, based on as-reported figures from SEC (XBRL) filings.
What is Aditxt, Inc. Common Stock's Diluted EPS (TTM)?
Aditxt, Inc. Common Stock's Diluted EPS (TTM) is -65.37, based on as-reported figures from SEC (XBRL) filings.
What is Aditxt, Inc. Common Stock's EBITDA Margin?
Aditxt, Inc. Common Stock's EBITDA Margin is -126063.3%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ADTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
REVENUE
Sales
YoY growth+1094.4%-86.6%-89.1%-97.7%
Cost of goods sold
Gross profit
% of revenue23.6%-7.3%2.1%-0.1%
OPERATING EXPENSES
General and administrative expenses $0 and $0 in stock-based compensation, respectively
Research and development $0 and $10,000 in stock-based compensation, respectively
Sales and marketing $0 and $0 in stock-based compensation, respectively—
Total operating expenses
% of revenue35897.1%1098718.4%419872.5%612788.2%
NET LOSS FROM OPERATIONS
% of revenue-35873.5%-1098725.6%-419870.3%-612788.3%
NET LOSS
% of revenue-133145.8%-1230882.6%-3236319.4%-736619.3%
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST
NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES
% of revenue-131159.8%-1432689.2%-3214626.3%-722789.6%
Net loss per share, basic (in Dollars per share)—
Net loss per share, diluted (in Dollars per share)—